Deborah Froh

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.3K citations · Full text

Mendelian Disorder, Genetics, Ivacaftor Combination Regimen +2

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 291 citations

Pulmonary Fibrosis, Medicine, Placebo-controlled Phase 3

Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early<i>Pseudomonas aeruginosa</i>Infection in Children With Cystic Fibrosis

Miriam M. Treggiari, George Retsch‐Bogart, Nicole Mayer-Hamblett et al. · Archives of Pediatrics and Adolescent Medicine · 2011 · 212 citations · Full text

Hyperpolarized HHe 3 MRI of the Lung in Cystic Fibrosis

Kimiknu Mentore, Deborah Froh, Eduard E. de Lange et al. · Academic Radiology · 2005 · 143 citations

Engineering, Medical Imaging, Biomedical Imaging +6

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 116 citations · Full text

Medicine, Hypertonic Saline, Dornase Alfa +1